


Please amend the claims as follows:

1. (Previously Amended) A process for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a *N*-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof,




(I)

which comprises reacting an intermediate of formula (II), an appropriate acid addition salt or a stereochemically isomeric form thereof



(II)

with an intermediate of formula (III), an appropriate acid addition salt or a *N*-oxide thereof



(III)

wherein W_1 represents a suitable leaving group, in the presence of a suitable solvent,

optionally followed by converting the free base into an acid addition salt by treatment with an acid, or alternatively, by converting the acid addition salt form into the free base by treatment

with alkali; and optionally followed by preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.

2. (Original) A process according to claim 1 wherein the solvent is acetonitrile.

3. Canceled.

4. Canceled.

5. Canceled.

6. Canceled.

7. Canceled.

8. Canceled.

9. Canceled.

10. (Previously Amended) A process according to claim 1 wherein the 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a *N*-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof, is 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E).

11. Canceled.

12. Canceled.

13. (Previously Presented) A process according to claim 1 wherein the solvent is 1-methyl-2-pyrrolidinone.


Please add claims 14-20 as follows:

14. (New) A process for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile (E) or a pharmaceutically acceptable acid addition salt thereof, wherein



(II)

is reacted with



(III)

wherein W_1 represents a suitable leaving group, optionally followed by converting free base into an acid addition salt by treatment with an acid.

15. (New) The process of claim 14, wherein the pharmaceutically acceptable acid addition salt is hydrochloric acid salt.

16. (New) The process of claim 14, wherein W_1 is halo.


17. (New) The process of claim 16, wherein W_1 is chloro.

18. (New) A process for the preparation of 4-[[4-[(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile (E) or a pharmaceutically acceptable acid addition salt thereof, wherein an acid addition salt of



(II)

is reacted with



(III)

wherein W_1 represents a suitable leaving group, optionally followed by converting the acid addition salt form into free base by treatment with alkali.

18. (New) The process of claim 17, wherein the pharmaceutically acceptable acid addition salt is hydrochloric acid salt.

19. (New) The process of claim 17, wherein W_1 is halo.

20. (New) The process of claim 19, wherein W_1 is chloro.